Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643862 · ClinicalTrials.gov registry record · Phase 1
Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02643862: Completed Phase 1 study, sponsored by Stanford University.
NCT02643862 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02643862, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food allergies (limited to 5 of those food allergens in IND 14831). In a 3:1 ratio, 36\* participants will receive Xolair for 16 weeks while 12\* will receive corresponding placebo instead of Xolair. 12 controls will be enrolled who will receive no OIT and no Xolair. These 12 controls are not part of the randomization. The total number of participants randomized to the two arms is 48\*.
Interventions
- DRUG Placebo
- DRUG Xolair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-03-18 |
| Est. Completion | 2016-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643862
The ClinicalTrials.gov registry entry for NCT02643862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02643862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643862 about?
NCT02643862 is a clinical study titled "Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients". This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food allergies (limited to 5 of those food allergens in IND 14831). In a 3:1 ratio, 36\* participants will receive Xolair...
What is the current status of trial NCT02643862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-03-18. Estimated completion is 2016-08-20.
What interventions are being tested in trial NCT02643862?
The interventions under investigation include: Placebo (DRUG), Xolair (DRUG).
Who is sponsoring clinical trial NCT02643862?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.